Skip to main content
SpringerLink
Log in

Glucagon and Diabetes

  • Chapter
Glucagon III

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 123))

Abstract

Since the review on glucagon and diabetes by Unger and Orci (1983) in volume 66/II of this series (Lefèbvre 1983a), several reviews on the role of glucagon in both insulin-dependent (IDDM) and non-insulin-dependent (NIDDM) diabetes mellitus have appeared (Gerich 1989; Lefèbvre et al. 1991; Unger and Orci 1995; Lefèbvre 1991, 1995). In this chapter, we will consider: (1) the diabetogenic effects of glucagon; (2) the morphology of the A cells in the islets of Langerhans of diabetic patients; (3) the data available on glucagon plasma levels in the various forms of diabetes mellitus; (4) the glucagon dysfunction that is present in diabetes; (5) the role of glucagon excess in the metabolic abnormalities of diabetes; and (6), briefly, the attempts to improve diabetes control by reducing excessive glucagon secretion and/or action. Specific characteristics of the diabetic state associated with the glucagonoma syndrome are reviewed in more detail in Chap. 15 of this volume while the search for new glucagon antagonists is considered in Chap. 8.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aguilar-Parada E, Eisentraut AM, Unger RH (1969) Effect of HB-419 induced hypoglycemia on pancreatic glucagon secretion. Horm Metab Res 1 [Suppl]: 48–50.

    Google Scholar 

  • Amer P, Einarsson K, Ewerth S, Livingston JN (1987) Altered action of glucagon on human liver in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30: 323–326

    Article  Google Scholar 

  • Assan R, Hautecouverture G, Guillemant S, Dauchy F, Protin P, Derot M (1969) Evolution de paramètres hormonaux (glucagon, cortisol et hormone somatotrope) et énergétiques (glucose, acides gras libres, glycérol) dans dix acidocétoses diabétiques graves traitées. Pathol Biol (Paris) 17: 1095–1105

    CAS  Google Scholar 

  • AvRuskin TW, Obilessetty V, Jabbar M, Prasad V, Greenfield E, Greig F, Juan CS (1994) Both glucagon excess and insulin deficiency characterize maturity-onset diabetes mellitus of youth ( MODY ). J Pediatr Endocrinol 7: 335–341

    Google Scholar 

  • Barnes AJ, Bloom SR, Mashiter K, Alberti KGMM, Smythe P, Turnell D (1977) Persistent metabolic abnormalities in diabetes in the absence of glucagon. Diabetologia 13: 71–75

    Article  PubMed  CAS  Google Scholar 

  • Baron AD, Schaeffer L, Shragg P, Kolterman OG (1987) Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36: 274–283

    Article  PubMed  CAS  Google Scholar 

  • Bergenstal R, Polonsky K, Pons G, Jaspan J, Rubenstein A (1983) Lack of glucagon response to hypoglycemia in type 1 diabetes after long-term optimal therapy with a continued subcutaneous insulin infusion pump. Diabetes 32: 398–402

    Article  PubMed  CAS  Google Scholar 

  • Best J, Judzewitsch RG, Pfeifer MA, Beard JC, Halter JB, Porte D Jr (1982) The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulindependent diabetes. Diabetes 31: 333–338

    Article  PubMed  CAS  Google Scholar 

  • Bonner-Weir S, Orci L (1982) New perspectives on the microvasculature of the islets of Langerhans in the rat. Diabetes 31: 883–889

    Article  PubMed  CAS  Google Scholar 

  • Bringer J, Mirouze J, Marchal G, Pham TC, Luyckx A, Lefèbvre P, Orsetti A (1981) Glucagon immunoreactivity and antidiabetic action of somatostatin in the totally duodeno-pancreatectomized and gastrectomized human. Diabetes 30: 851–856

    Article  PubMed  CAS  Google Scholar 

  • Campbell PJ, Mandarino LJ, Gerich JE (1988) Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism 37: 15–21

    Article  PubMed  CAS  Google Scholar 

  • Carlson MG, Snead WL, Campbell PJ (1993) Regulation of free fatty acid metabolism by glucagon. J Clin Endocrinol Metab 77: 11–15

    Article  PubMed  CAS  Google Scholar 

  • Carpentier JL, Luyckx AS, Lefèbvre PJ (1975) Influence of metformin on arginineinduced glucagon secretion in human diabetes. Diabete Metab 1: 23–28

    CAS  Google Scholar 

  • Claus TH, Park CR, Pilkis SJ (1983) Glucagon and gluconeogenesis. In: Lefèbvre PJ (ed) Glucagon I. Springer, Berlin Heidelberg New York, p 315 (Handbook of experimental pharmacology, vol 66/I)

    Google Scholar 

  • Consoli A, Nurjhan N, Kennedy F, Gerich J (1987) Accelerated gluconeogenesis accounts for all of the increase in basal hepatic glucose output (HGO) of noninsulin-dependent diabetes mellitus (NIDDM) (abstract). Diabetes 36 [Suppl 1]: 4A

    Google Scholar 

  • Cryer P, Gerich J (1985) Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus. N Engl J Med 313: 232–241

    Article  PubMed  CAS  Google Scholar 

  • Davies RR, Turner SJ, Alberti KGMM, Johnston DG (1989) Somatostatin analogues in diabetes mellitus. Diabetic Med 6: 103–111

    Article  PubMed  CAS  Google Scholar 

  • De Feo P, Perriello G, Torlone E, Fanelli C, Ventura MM, Santeusanio F, Brunetti P, Gerich JE, Bolli GB (1991) Evidence against important catecholamine compensation for absent glucagon counterregulation. Am J Physiol 260 (Endocrinol Metab 23): E203 - E212

    PubMed  Google Scholar 

  • Dupré J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ (1995) Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44: 626–630

    Article  PubMed  Google Scholar 

  • Fanelli CG, Epifano L, Rambotti AM, Pampanelli S, Di Vincenzo A, Modarelli F, Lepore M, Annibale B, Ciofetta M, Bottini P, Porcellati F, Scionti L, Santeusanio F, Brunetti P, Bolli GB (1993) Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 42: 1683–1689

    Article  PubMed  CAS  Google Scholar 

  • Gerich J (1977) On the causes and consequences of abnormal glucagon secretion in human diabetes mellitus. In: Foà PP, Bajaj JS, Foà NL (eds) Glucagon: its role in physiology and clinical medicine. Springer, Berlin Heidelberg New York, p 617

    Google Scholar 

  • Gerich JE (1983) Glucagon as a counterregulatory hormone. In: Lefèbvre PJ (ed) Glucagon II. Springer, Berlin Heidelberg New York, p 275 (Handbook of experimental pharmacology, vol 66/II)

    Google Scholar 

  • Gerich JE (1989) Abnormal glucagon secretion in type-2 (non insulin-dependent) diabetes mellitus: causes and consequences. In: Creutzfeldt W, Lefèbvre PJ (eds) Diabetes mellitus: pathophysiology and therapy. Springer, Berlin Heidelberg New York, p 127

    Google Scholar 

  • Gerich J, Langlois M, Noacco C, Karam J, Forsham P (1973) Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha-cell defect. Science 182: 171–173

    Article  PubMed  CAS  Google Scholar 

  • Gerich JE, Lorenzi M, Bier DM, Schneider V, Tsalikian E, Karam JH, Forsham PH (1975) Prevention of human diabetic ketoacidosis by somatostatin: evidence for an essential role of glucagon. N Engl J Med 292: 985–989

    Article  PubMed  CAS  Google Scholar 

  • Gerich JE, Lorenzi M, Bier DM, Tsalikian E, Schneider V, Karam JH, Forsham PH (1976) Effect of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. J Clin Invest 57: 875–884

    Google Scholar 

  • Greenbaum CJ, Havel PJ, Taborsky GJ Jr, Klaff LJ (1991) Intra-islet insulin permits glucose to directly suppress pancreatic A cell function. J Clin Invest 88: 767–773

    Article  PubMed  CAS  Google Scholar 

  • Grodsky GM, Epstein GH, Franska R, Karam JH (1977) Pancreatic action of the sulfonylureas. Fed Proc 36: 2714–2719

    PubMed  CAS  Google Scholar 

  • Hamaguchi T, Fukushima H, Uehara M, Wada S, Shirotani T, Kishikawa H, Ichinose K, Yamaguchi K, Shichiri M (1991) Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic alpha cells. Diabetologia 34: 801–806

    Article  PubMed  CAS  Google Scholar 

  • Heller SR, Macdonald IA, Tattersall RB (1987) Counterregulation in type 2 (noninsulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses, up to ten years after diagnosis. Diabetologia 30: 924–929

    Article  PubMed  CAS  Google Scholar 

  • Hendrick GK, Wasserman DH, Frizzell RT, Williams PE, Lacy DB, Jaspan JB, Cherrington AD (1992) Importance of basal glucagon in maintaining hepatic glucose production during a prolonged fast in conscious dogs. Am J Physiol 263 (Endocrinol Metab 26): E541 - E549

    PubMed  CAS  Google Scholar 

  • Kajinuma H, Kuzuya T, Ide T (1974) Effects of hypoglycemic sulfonamides on glucagon and insulin secretion in ducks and dogs. Diabetes 23: 412–417

    PubMed  CAS  Google Scholar 

  • Kawamori R, Schichiri M, Kikuchi M, Yamasaki Y, Abe H (1980) Perfect normalization of excessive glucagon responses to intravenous arginine in human diabetes mellitus with the artificial beta-cell. Diabetes 29: 762–765

    Article  PubMed  CAS  Google Scholar 

  • Kelley D, Mitrakou A, Marsh H, Schwenk F, Benn J, Sonnenberg G, Archangeli M, Aoki T, Sorenson T, Berger M, Sonksen P, Gerich J (1988) Skeletal muscle glycolysis, oxidation and storage of an oral glucose load. J Clin Invest 81: 1563–1571

    Article  PubMed  CAS  Google Scholar 

  • Kennedy F, Bolli G, Go V, Cryer P, Gerich J (1987) The significance of impaired pancreatic polypeptide and epinephrine responses to hypoglycemia in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64: 602–608

    Article  PubMed  CAS  Google Scholar 

  • Kisanuki K, Kishikawa H, Araki E, Shirotani T, Uehara M, Isami S, Ura S, Jinnouchi H, Miyamura N, Shichiri M (1995) Expression of insulin receptor on clonal pancreatic alpha cells and its possible role for insulin-stimulated negative regulation of glucagon secretion. Diabetologia 38: 422–429

    Article  PubMed  CAS  Google Scholar 

  • Korànyi L (1983) Lipolytic effect of glucagon on perifused isolated human fat cells (abstract). Diabetologia 25: 172

    Google Scholar 

  • Krzentowski G, Scheen A, Castillo M, Luyckx AS, Lefèbvre PJ (1983) A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: I. Metabolic and hormonal consequences and scheme for a prompt return to adequate control. Diabetologia 24: 314–318

    Article  PubMed  CAS  Google Scholar 

  • Lang DA, Matthews DR, Barnett M, Turner RC (1981) Brief irregular oscillations of basal plasma insulin and glucose concentrations in diabetic man. Diabetes 30: 435–439

    Article  PubMed  CAS  Google Scholar 

  • Larsson H, Berglund G, Ahren B (1995) Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. J Clin Endocrinol Metab 80: 1778: 1782

    Google Scholar 

  • Laube H, Fussganger R, Goberna R, Schroder K, Straub K, Sussman K, Pfeiffer EF (1971) Effects of tolbutamide on insulin and glucagon secretion of the isolated perfused rat pancreas. Horm Metab Res 3: 238–242

    Article  PubMed  CAS  Google Scholar 

  • Lecomte MJ, Luyckx AS, Lefèbvre PJ (1977) Plasma glucagon and diabetes control in maturity-onset type diabetics. Respective effects of diet, placebo and glipizide. Diabete Metab 3: 2714–2719

    Google Scholar 

  • Lefèbvre PJ (1983a) Glucagon II. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 66/II)

    Google Scholar 

  • Lefèbvre PJ (1983b) Glucagon and adipose tissue lipolysis. In: Lefèbvre PJ (ed) Glucagon I. Springer, Berlin Heidelberg New York, p 418 (Handbook of experimental pharmacology, vol 66/I)

    Google Scholar 

  • Lefèbvre PJ (1991) Abnormal secretion of glucagon. In: Samols E (ed) The endocrine pancreas. Raven, New York, p 191

    Google Scholar 

  • Lefèbvre PJ (1995) Glucagon and its family revisited. Diabetes Care 18: 715–730

    PubMed  Google Scholar 

  • Lefèbvre PJ, Luyckx AS (1977) Factors controlling gastric-glucagon release. J Clin Invest 59: 716–722

    Article  PubMed  Google Scholar 

  • Lefèbvre PJ, Luyckx AS (1978) Glucose and insulin in the regulation of glucagon release from the isolated perfused dog stomach. Endocrinology 103: 1579–1582

    Article  PubMed  Google Scholar 

  • Lefèbvre PJ, Luyckx AS (1979) Glucagon and diabetes: a reappraisal. Diabetologia 16: 347–354

    Article  PubMed  Google Scholar 

  • Lefèbvre PJ, Luyckx AS (1983) Extrapancreatic glucagon and its regulation. In: Lefèbvre PJ (ed) Glucagon II Springer, Berlin Heidelberg New York, p 205 (Handbook of experimental pharmacology, vol 66/II)

    Google Scholar 

  • Lefèbvre PJ, Scheen AJ (1992) Update on the treatment of NIDDM. In: Lefèbvre PJ, Standl E (eds) New aspects in diabetes. De Gruyter, Berlin, p 71

    Google Scholar 

  • Lefèbvre PJ, Luyckx AS, Mosora F, Lacroix M, Pirnay F (1978) Oxidation of an exogenous glucose load using naturally labelled 13C-glucose. Effect of butylbiguanide therapy in obese mildly diabetic subjects. Diabetologia 14: 39–45

    Article  PubMed  Google Scholar 

  • Lefèbvre PJ, Paolisso G, Scheen AJ, Henquin JC (1987) Pulsatility of insulin and glucagon release: physiological significance and pharmacological implications. Diabetologia 30: 443–452

    Article  PubMed  Google Scholar 

  • Lefèbvre PJ, Paolisso G, Scheen A (1991) The role of glucagon in non-insulin-dependent (type 2) diabetes mellitus. In: Sakamoto N, Angel A, Hotta H (eds) New directions in research and clinical works for obesity and diabetes mellitus. Elsevier Science, Amsterdam, p 25

    Google Scholar 

  • Lindsey C, Faloona G, Unger RH (1974) Plasma glucagon in non-ketotic hyperosmolar coma. JAMA 229: 1771–1773

    Article  PubMed  CAS  Google Scholar 

  • Liu D, Moberg E, Kollind M, Lins P-E, Adamson U (1991) A high concentration of circulating insulin suppresses the glucagon response to hypoglycemia in normal man. J Clin Endocrinol Metab 73: 1123–1128

    Article  PubMed  CAS  Google Scholar 

  • Loubatières AL, Loubatières-Mariani MM, Alric R, Ribes G (1974) Tolbutamide and glucagon secretion. Diabetologia 10: 271–276

    PubMed  Google Scholar 

  • Luyckx AS (1983) Pharmacological compounds affecting glucagon secretion. In: Lefèbvre PJ (ed) Glucagon II. Springer, Berlin Heidelberg New York, p 175 (Handbook of experimental pharmacology, vol 66/Il)

    Google Scholar 

  • Luyckx AS, Lefèbvre PJ (1983) Prostaglandins and glucagon secretion. In: Lefèbvre PJ (ed) Glucagon II. Springer, Berlin Heidelberg New York, p 83 (Handbook of experimental pharmacology, vol 66/II)

    Google Scholar 

  • Luyckx AS, Mendoza E, Lefèbvre PJ (1981) Failure of indomethacin to affect arginineinduced C-peptide and glucagon release in insulin-treated diabetics. Major role of residual B-cell function in conditioning the magnitude of the blood glucose rise after intravenous arginine. Diabetologia 21: 376–382

    Article  PubMed  CAS  Google Scholar 

  • Magnusson I, Rothman DL, Gerard DP, Katz LD, Shulman GI (1995) Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration. Diabetes 44: 185–189

    Article  PubMed  CAS  Google Scholar 

  • Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH (1984) Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 74: 2296–2299

    Article  PubMed  CAS  Google Scholar 

  • McGarry JD, Foster DW (1983) Glucagon and ketogenesis. In: Lefèbvre PJ (ed) Glucagon I. Springer, Berlin Heidelberg New York, p 383 (Handbook of experimental pharmacology, vol 66/I)

    Google Scholar 

  • Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I, Durrant J, Cryer P, Gerich J (1991) Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 260 (Endocrinol Metab 23): E67 - E74

    PubMed  CAS  Google Scholar 

  • Mitrakou A, Fanelli C, Veneman T, Perriello G, Calderone S, Platanisiotis D, Rambotti A, Raptis S, Brunetti P, Cryer P, Gerich J, Bolli G (1993) Reversibility of unawareness of hypoglycemia in patients with insulinomas. N Engl J Med 329: 834–839

    Article  PubMed  CAS  Google Scholar 

  • Müller W, Faloona G, Unger RH (1973) Hyperglucagonemia in diabetic ketoacidosis: Its prevalence and significance. Am J Med 54: 52–57

    Article  PubMed  Google Scholar 

  • Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741–744

    Article  PubMed  CAS  Google Scholar 

  • Ohneda A, Sato M, Matsuda K, Itabashi H, Horigome K, Chiba M, Yamagata S (1974) Suppression of pancreatic glucagon secretion by tolbutamide in dogs. Horm Metab Res 6: 478–483

    Article  PubMed  CAS  Google Scholar 

  • Ohneda A, Ishii S, Horigome K, Yamagata S (1975) Glucagon response to arginine after treatment of diabetes mellitus. Diabetes 24: 811–819

    Article  PubMed  CAS  Google Scholar 

  • Orci L, Bordi C, Unger RH, Perrelet A (1983) Glucagon- and glicentin-producing cells. In: Lefèbvre PJ (ed) Glucagon I. Springer, Berlin Heidelberg New York, p 57 (Handbook of experimental pharmacology, vol 66/I)

    Google Scholar 

  • Paolisso G, Sgambato S, Gentile S, Memoli P, Varricchio M, D’Onofrio F (1988a) Advantageous metabolic effects of pulsatile insulin delivery in non-insulindependent diabetic subjects. J Clin Endocr Metab 67: 1005–1010

    Article  PubMed  CAS  Google Scholar 

  • Paolisso G, Sgambato S, Torella R, Varricchio M, Scheen A, D’Onofrio F, Lefèbvre PJ (1988b) Pulsatile insulin delivery is more efficient than continuous infusion in modulating islet cell function in normal subjects and patients with Type 1 diabetes. J Clin Endocrinol Metab 66: 1220–1226

    Article  PubMed  CAS  Google Scholar 

  • Pek S, Fajans SS, Floyd JC, Knopf RF, Conn JW (1972) Failure of sulfonylureas to suppress plasma glucagon in man. Diabetes 21: 216–222

    PubMed  CAS  Google Scholar 

  • Perea A, Clemente F, Martinell J, Villanueva-Penacarrillo, Valverde I (1994) Lipolytic effect of glucagon in human isolated adipocytes (abstract). Diabetologia 37 [Suppl 1]:Al29

    Google Scholar 

  • Perea A, Clemente F, Martinell J, Nillanueva-Penacarrillo, Valverde I (1995) Physiological effect of glucagon in human isolated adipocytes. Horm Metab Res 27: 372–375

    Article  PubMed  CAS  Google Scholar 

  • Pipeleers DG, In’tveld PA, Van De Winkel (1988) Death of the pancreatic B cell. In: Lefèbvre PJ, Pipeleers DG (eds) The pathology of the endocrine pancreas in diabetes. Springer, Berlin Heidelberg New York, p 106

    Google Scholar 

  • Rahier J (1988) The diabetic pancreas: a pathologist’s view. In: Lefèbvre PJ, Pipeleers DG (eds) The pathology of the endocrine pancreas in diabetes. Springer, Berlin Heidelberg New York, p 17

    Google Scholar 

  • Rahier J, Goebbels RM, Henquin JC (1983) Cellular composition of the human diabetic pancreas. Diabetologia 24: 366–371

    Article  PubMed  CAS  Google Scholar 

  • Reaven GM, Chen Y-DI, Golay A, Swilocki ALM, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64: 106–110

    Article  PubMed  CAS  Google Scholar 

  • Richter WO, Robl W, Schwandt P (1989) Human glucagon and vasoactive intestinal polypeptide (VIP) stimulate free fatty acid release from human adipose tissue in vitro. Peptides 10: 333

    Article  PubMed  CAS  Google Scholar 

  • Ritzel R, ørskov C, Holst JJ, Nauck MA (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 38: 720–725

    Article  PubMed  CAS  Google Scholar 

  • Roden M, Perseghin G, Hwang J-H, Petersen KF, Cline G, Rothman DL, Shulman GI (1995) Important role for glucagon in the regulation of hepatic glycogen synthesis and turnover (abstract). Diabetologia 38 [Suppl 1]: A66

    Google Scholar 

  • Saito K, Yaginuma N, Takahashi T (1979) Differential volumetry of A, B and D cells in the pancreatic islets of diabetic and non diabetic subjects. Tohoku J Exp Med 129: 273–283

    Article  PubMed  CAS  Google Scholar 

  • Samols E, Harrison J (1976) Intraislet negative insulin-glucagon feedback. Metabolism 25 [Suppl 1]: 1443–1447

    Article  PubMed  CAS  Google Scholar 

  • Samols E, Stagner J (1991) Intraislet and islet-acinar portal systems and their signifi-cance. In: Samols E (ed) The endocrine pancreas. Raven, New York, p 93

    Google Scholar 

  • Samols E, Tyler J, Miahle (1969) Suppression of pancreatic glucagon release by the hypoglycemic sulfonylureas. Lancet I: 174–176

    CAS  Google Scholar 

  • Samols E, Weir GC, Bonner-Weir S (1983) Intraislet insulin-glucagon-somatostatin relationship. In: Lefèbvre PJ (ed) Glucagon II. (Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 66/I)

    Google Scholar 

  • Samols E, Stagner J, Ewart RBL, Marks V (1988) The order of islet perfusion is B-AD in the perfused rat pancreas. J Clin Invest 82: 350–354

    Article  PubMed  CAS  Google Scholar 

  • Savage PJ, Bennion LJ, Bennett PH (1979) Normalization of insulin and glucagon secretion in ketosis-resistant diabetes mellitus with prolonged diet therapy. J Clin Endocrinol Metab 49: 830–833

    Article  PubMed  CAS  Google Scholar 

  • Scheen AJ, Lefèbvre PJ (1993) Pharmacological treatment of the obese diabetic patient. Diabete Matab 19: 547–559

    CAS  Google Scholar 

  • Scheen AJ, Lefèbvre PJ (1995) Antihyperglycaemic agents. Drug interactions of clinical importance. Drugs Safety 12: 32–45

    Article  CAS  Google Scholar 

  • Scheen AJ, Krzentowski G, Castillo M, Lefèbvre PJ, Luyckx AS (1983) A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin. Diabetologia 24: 319–325

    Article  PubMed  CAS  Google Scholar 

  • Scheen AJ, Gillet J, Rosenthaler J, Guiot J, Henrivaux Ph, Jandrain B, Lefèbvre PJ (1989) Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in Type 1 (insulin-dependent) diabetic patients. Diabetologia 32: 801–809

    Article  PubMed  CAS  Google Scholar 

  • Stalmans W (1983) Glucagon and liver glycogen metabolism. In: Lefèbvre PJ (ed) Glucagon I. Springer, Berlin Heidelberg New York, p 291 (Handbook of experimental pharmacology, vol 66/I)

    Google Scholar 

  • Starke A, Grundy S, McGarry JD, Unger RH (1985) Correction of hyperglycemia with phloridizin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes. Proc Natl Acad Sci USA 82: 1544–1546

    Article  PubMed  CAS  Google Scholar 

  • Stefan Y, Orci L, Malaisse-Lagae F, Perrelet A, Patel Y, Unger RH (1982) Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes 31: 694–700

    Article  PubMed  CAS  Google Scholar 

  • Stevenson RW, Steiner KE, Davis MA, Hendrick GK, Williams PE, Lacy WW, Brown L, Donahue P, Lacy DB, Cherrington AD (1987) Similar dose responsiveness of hepatic glycogenolysis and gluconeogenesis to glucagon in vivo. Diabetes 36: 382–389

    Article  PubMed  CAS  Google Scholar 

  • Takahashi K, Yamatani K, Hara M, Sasaki H (1994) Gliclazide directly suppresses arginine-induced glucagon secretion. Diab Res Clin Pract 24: 143–151

    Article  CAS  Google Scholar 

  • Tamborlane WV, Sherwin RS, Hendler R, Felig P (1977) Metabolic effects of somatostatin in maturity-onset diabetes. N Engl J Med 297: 181–183

    Article  PubMed  CAS  Google Scholar 

  • Under RH (1978) Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism 27: 1691–1709

    Article  Google Scholar 

  • Unger RH, Orci L (1981) Glucagon and the A cell. Physiology and pathophysiology. N Engl J Med 304:1518–1524, 1575–1580

    Google Scholar 

  • Unger RH, Orci L (1983) Glucagon in diabetes mellitus. In: Lefèbvre PJ (ed) Glucagon II. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 66/II)

    Google Scholar 

  • Unger RH, Orci L (1995) Glucagon secretion, alpha cell metabolism, and glucagon action. In: DeGroodt LJ (ed) Endocrinology, vol 2, 3rd edn. Saunders, Philadelphia, 1337

    Google Scholar 

  • Van Schravendijk CFH, Foriers A, Hoghe-Peters EL, Rogiers B, De Meyts P, Sodoyez JC, Pipeleers DG (1985) Pancreatic hormone receptors on islet cells. Endocrinology 117: 841–848

    Article  PubMed  Google Scholar 

  • Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J (1993) Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia. Diabetes 42: 1233–1237

    Article  PubMed  CAS  Google Scholar 

  • White NH, Skor DA, Cryer PE, Levandorsky LA, Bier DM (1983) Identification of type-1 diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med 308: 485–491

    Article  PubMed  CAS  Google Scholar 

  • Willms B, Werner J, Creutzfeldt W, ørskov C, Holst JJ, Nauck M (1994) Inhibition of gastric emptying by glucagon-like peptide-1 (7–36 amide) in patients with type-2 diabetes mellitus (abstract). Diabetologia 37 [Suppl 1]: A118

    Google Scholar 

  • Willms B, Kleine N, Creutzfeldt W, ørskov C, Holst J, Nauck M (1995) Glucagon-like peptide 1 (7–36 amide) lowers blood glucose also in type-l-diabetic patients (abstract). Diabetologia 38 [Suppl 1]: A40

    Google Scholar 

Download references

Authors
  1. P. J. Lefèbvre
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, Centre Hospitalier Universitaire de Liège, B-4000, Liège 1, Belgium

    Pierre J. Lefèbvre M.D., Ph.D., FRCP

  2. Division of Diabetes, Nutrition, and Metabolic Disorders, C.H.U. Sart Tilman, B-4000, Liège 1, Belgium

    Pierre J. Lefèbvre M.D., Ph.D., FRCP

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lefèbvre, P.J. (1996). Glucagon and Diabetes. In: Lefèbvre, P.J. (eds) Glucagon III. Handbook of Experimental Pharmacology, vol 123. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61150-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-61150-6_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64718-5

  • Online ISBN: 978-3-642-61150-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation